Catalog No.
Product Name
Application
Product Information
Citations
-
P2 receptor/NAADP receptor Antagonist
PPADS is a reversible competitive antagonist of P2X receptors, specifically targeting P2X1 and P2X3, with IC50 values of 68 nM and 214 nM, respectively. It demonstrates significant anti-nociceptive effects in mouse models of neuropathic pain and inhibits pro-inflammatory cytokines such as IL-1β and IL-6, as well as nitric oxide synthases. Additionally, PPADS effectively blocks ATP-mediated inward currents in recombinant rat P2X receptors and reduces contractions in rabbit bladder detrusor muscle induced by purinergic nerve stimulation. This compound is valuable for research on neuropathic pain mechanisms and related therapeutic interventions. -
P2X7R Selective Allosteric Antagonist
SMW139 is a selective allosteric antagonist of the P2X7 receptor, demonstrating a Ki value of 32 nM for human P2X7R. This compound exhibits potential in modulating inflammatory responses and has applications in research related to Alzheimer's disease and multiple sclerosis. With a half-life of 47 minutes in rat liver microsomes, SMW139 serves as a valuable tool for investigating the therapeutic effects on P2X7R-mediated pathways. -
AChE/ACP/ALP Inhibitor
Trimyristin is a potent inhibitor of acetylcholinesterase (AChE) as well as acid and alkaline phosphatase (ACP/ALP). It has demonstrated significant inhibitory effects on AChE, ACP, and ALP activities in the nervous tissue of Lymnaea acuminata, with IC50 values of 0.11 mM, 0.16 mM, and 0.18 mM, respectively. This compound is valuable for research applications focused on neurological pathways and enzyme activity modulation. -
CaMKP/CaMKP-N Inhibitor
CaMKP Inhibitor Sodium targets Ca2+/neutral protein-dependent protein kinase (CaMKP) and its nuclear variant (CaMKP-N), exhibiting IC50 values of 6.4 μM and 6.6 μM, respectively. This compound suppresses CaMKP-mediated phospho-CaMKI hydrolysis while leaving protein phosphatases PP2C and calcineurin unaffected. CaMKP plays a critical role in various cellular processes involving serine/threonine phosphorylation, making this inhibitor valuable for research into calcium-dependent signaling pathways and protein regulation. -
Stable Isotope
Trimyristin-d15 is a deuterium-labeled derivative of Trimyristin, a naturally occurring compound extracted from Myristica fragrans. This reagent effectively inhibits acetylcholinesterase (AChE), as well as acid and alkaline phosphatase (ACP/ALP) activities in the nervous tissue of Lymnaea acuminata, with IC50 values of 0.11 mM, 0.16 mM, and 0.18 mM, respectively. Trimyristin-d15 serves as a valuable tool for biochemical research and enzyme activity studies, particularly in exploring the mechanisms of neurotoxicity and molluscicidal action. -
α4β2 nAChR Agonist
TC-2559 free base is an agonist of the α4β2 nicotinic acetylcholine receptor (nAChR), demonstrating an EC50 value of 0.18 μM. It exhibits reduced potency on β4-containing nAChR subtypes, such as α2β4, α4β4, and α3β4, with EC50 values between 10-30 µM. Research indicates that TC-2559 enhances dopamine neuron activity in the ventral tegmental area, which may influence excitability and aggression. Additionally, it possesses anti-inflammatory effects via STAT3 inhibition, proving beneficial in models of mechanical allodynia and cognitive deficits. This compound is useful for investigations into nerve pain and related neurological conditions. -
AChE Inhibitor
Propoxur is a reversible competitive inhibitor of acetylcholinesterase (AChE) that effectively penetrates the blood-brain barrier. This compound induces neurotoxicity by inhibiting AChE activity, resulting in the accumulation of acetylcholine, thereby causing neurological dysfunction. In addition, Propoxur promotes MMP-2 expression and enhances tumor cell migration and invasion through the generation of reactive oxygen species (ROS) and the activation of the ERK/Nrf2 signaling pathway. It is also utilized as a carbamate insecticide for managing pests in turf, forestry, and household environments. -
Peptide
PHF6 (VQIVYK) is a peptide that facilitates the self-assembly and aggregation of the full-length tau protein, specifically targeting the third microtubule-binding repeat region of tau. This peptide is instrumental in studies of tau pathology associated with neurodegenerative diseases, particularly in understanding the mechanisms underlying tau aggregation and its implications in tau-related disorders. Its unique structure makes it a valuable tool for investigating tau fibrillogenesis and potential therapeutic interventions. -
COX-2 Inhibitor
COX-2-IN-43 is a selective COX-2 inhibitor with an IC50 of 0.247 μM for COX-2 and 0.983 μM for COX-1. This compound demonstrates significant biological activity by inhibiting cancer cell proliferation and colonization while inducing apoptosis. It is valuable for research applications targeting inflammatory diseases and cancer therapeutics. -
Stable Isotope
Galanthamine-O-methyl-d3 is a deuterium-labeled derivative of Galanthamine, a potent inhibitor of acetylcholinesterase (AChE) with an IC50 value of 500 nM. This stable isotope-labeled compound is primarily utilized in pharmacokinetic and metabolic studies. It serves as a valuable tool for investigating the pharmacological dynamics and biochemical pathways associated with cholinergic activity. -
Drug Metabolite
3-O-Methyltolcapone-d4 is a deuterium-labeled metabolite of Tolcapone, which serves as a selective and potent inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 773 nM. This compound is utilized in research focused on cancer and neurological disorders, including Parkinson's disease and neuroblastoma, due to its ability to inhibit α-synuclein and Aβ42 oligomerization, promote oxidative stress, and induce apoptosis in cancer cells. 3-O-Methyltolcapone-d4 provides a valuable tool for studying the metabolic pathways of Tolcapone and its therapeutic implications. -
Stable Isotope
Carbaryl-d7 is a deuterium-labeled derivative of Carbaryl, which functions as an acetylcholinesterase inhibitor. By suppressing the breakdown of acetylcholine in the synaptic cleft, Carbaryl-d7 leads to an accumulation of acetylcholine, potentially resulting in neurotoxic effects. This stable isotope is primarily utilized in chemical research to study the enzymatic action and biological effects of Carbaryl and its derivatives. -
COX Inhibitor
Metamizole hemimagnesium is a cyclooxygenase (COX) inhibitor with anti-inflammatory and antioxidant properties. This compound effectively reduces body temperature and has been shown to decrease levels of C-reactive protein (CRP) and interleukin 6 (IL-6). Metamizole hemimagnesium also inhibits cell proliferation and promotes apoptosis. It is utilized in research applications focused on inflammation and fever modulation. -
Drug Metabolite
Tolcapone 3-β-D-glucuronide is a drug metabolite derived from Tolcapone, which serves as a selective and potent inhibitor of catechol-O-methyltransferase (COMT). While Tolcapone exhibits notable pharmacological activity, Tolcapone 3-β-D-glucuronide itself is pharmacologically inactive. Research indicates that Tolcapone plays a role in inhibiting α-synuclein and Aβ42 oligomerization, contributing to oxidative stress, cancer cell apoptosis, and reactive oxygen species (ROS) production. This metabolite is valuable for investigations into cancer mechanisms and neurological disorders, including Parkinson's disease and neuroblastoma. -
Stable Isotope
Galanthamine-d3 hydrochloride is a deuterium-labeled derivative of Galanthamine, primarily used as a stable isotope. This compound serves as a useful tool in pharmacokinetic studies and metabolic research, enabling the investigation of drug metabolism and distribution. Galanthamine-d3 hydrochloride plays a significant role in understanding the mechanisms of action of acetylcholinesterase inhibitors and their effects on neurological processes. -
COX Inhibitor
Ketorolac hydrochloride is a non-steroidal anti-inflammatory drug (NSAID) that acts as a nonselective inhibitor of cyclooxygenase (COX), with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. It is utilized in the study of various ophthalmic conditions, including allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, Ketorolac hydrochloride functions as a DDX3 inhibitor, making it relevant for cancer research applications. -
Anticancer Agent
Lanuginosine is an alkaloid with demonstrated anticancer activity. It induces apoptosis and inhibits acetylcholinesterase (AChE) with an IC50 of 10.9 μM, in addition to preventing amyloid-beta (Aβ) aggregation. This compound exhibits potent anticancer effects against various malignancies, including hepatocellular carcinoma, human promyelocytic leukemia, chronic myeloid leukemia, melanoma, and brain tumors. Lanuginosine is also valuable for research related to Alzheimer's disease and its therapeutic strategies. -
PKC/CaMKII Activator
Junicedric acid is a diterpenoid compound that functions as an activator of Protein Kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII). This compound exhibits neuroprotective properties by elevating intracellular calcium levels in hippocampal neurons, thereby mitigating amyloid-β oligomer-induced synaptic protein loss, apoptosis, and inhibition of long-term potentiation (LTP). Junicedric acid serves as a valuable tool for investigating the pathological mechanisms underlying neurodegenerative diseases, including Alzheimer’s disease. -
Stable Isotope
Carbaryl-d3 is a deuterium-labeled variant of Carbaryl, characterized as an acetylcholinesterase inhibitor. This compound prevents the breakdown of acetylcholine in the synaptic cleft, resulting in its accumulation and subsequent neurotoxic effects. Carbaryl-d3 is employed in research related to neurotoxicity mechanisms and may serve as a tool for studying the pharmacokinetics and metabolic pathways of Carbaryl. Its stable isotope labeling enhances analytical precision in experimental applications. -
COX Inhibitor
Meloxicam sodium is a selective cyclooxygenase (COX) inhibitor, primarily targeting COX-2 with an IC50 of 0.49 μM while exhibiting a higher IC50 of 36.6 μM for COX-1. This non-steroidal anti-inflammatory agent is capable of crossing the blood-brain barrier, making it suitable for research applications involving central nervous system inflammation and pain management. Meloxicam sodium is widely utilized in studies assessing the efficacy of anti-inflammatory therapies. -
COX-1/2 Inhibitor
Taraxerol acetate is an inhibitor of COX-1 and COX-2, exhibiting IC50 values of 116.3 μM and 94.7 μM, respectively. This compound demonstrates notable anticancer properties and has been shown to induce apoptosis in cancer cells. Taraxerol acetate is valuable for research applications focusing on inflammation, pain relief, and cancer treatment mechanisms. -
Apoptosi
Pamiparib maleate is a highly potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP), targeting apoptotic pathways. This compound effectively penetrates the blood-brain barrier, inducing neurotoxicity manifesting as cerebral hemorrhage, brain atrophy, and movement disorders in zebrafish embryos. It regulates critical enzymes such as acetylcholinesterase (AChE) and adenosine triphosphatase (ATPase), leading to increased oxidative stress that triggers apoptosis and affects the expression of neurodevelopment-related genes. Additionally, pamiparib maleate downregulates the Notch signaling pathway, providing insights into its potential neurotoxic effects during embryonic development and its relevance in neuropharmacology research. -
γ-secretase Inhibitor
MRK 003 is a selective and orally bioavailable inhibitor of γ-secretase. It demonstrates significant reduction of Aβ peptide production in the brain in vivo, making it a valuable tool for Alzheimer's disease research. Additionally, MRK 003 induces caspase-dependent apoptosis and inhibits tumor cell proliferation both in vitro and in vivo, supporting its potential applications in cancer research. -
MAO-B/Acetylcholinesterase Inhibitor
MAO-B-IN-26 is a selective inhibitor of monoamine oxidase B (MAO-B) and acetylcholinesterase, demonstrating neuroprotective properties against β-amyloid (Aβ) induced cytotoxicity in SH-SY5Y cells. This compound effectively mitigates morphological alterations, reactive oxygen species (ROS) generation, and membrane damage associated with neurodegeneration. Additionally, MAO-B-IN-26 suppresses Aβ-induced autophagy and apoptosis, making it a valuable tool for research focused on therapeutic strategies for Alzheimer's disease. -
P2Y6 Receptor Agonist
PSB 0474 (3-phenacyl-UDP) is a selective and potent agonist of the P2Y6 receptor, exhibiting an EC50 of 70 nM. This compound modulates key biological activities, including the inhibition of cell proliferation and the enhancement of nitric oxide release in astrocytes and microglia. Additionally, PSB 0474 promotes apoptosis in astrocytes, making it a valuable tool for research in neurobiology and cell signaling pathways. -
P2Y6 Agonist
MRS2693 ammonium is a selective agonist targeting the P2Y6 receptor, exhibiting an EC50 of 0.015 μM. This compound demonstrates significant biological activity by protecting C2C12 skeletal muscle cells from TNFα-induced apoptosis and reducing NF-kB activation. Additionally, MRS2693 ammonium activates the ERK1/2 signaling pathway and has shown cytoprotective effects in a mouse model of ischemia-reperfusion injury, making it a valuable tool for research in cellular protection and signaling pathways. -
P2Y2 Agonist
Diquafosol is a potent P2Y2 receptor agonist that plays a significant role in modulating cellular responses associated with inflammation and apoptosis. It exhibits the ability to inhibit apoptotic pathways and reduce reactive oxygen species (ROS) generation, thereby promoting cell survival. Diquafosol is primarily used in research related to dry eye therapies, providing valuable insights into potential treatment strategies for this condition. -
Diallyl Tetrasulfide
Diallyl tetrasulfide functions as an antioxidant, primarily by mitigating cadmium-induced neurotoxicity and oxidative liver injury. This compound has demonstrated the ability to regulate acetylcholinesterase and adenosine triphosphatase activities, as well as protect against oxidative stress in the brain and liver tissues of animal models. Diallyl tetrasulfide also inhibits lipid peroxidation and reduces reactive oxygen species (ROS) production, thereby enhancing cell viability and decreasing apoptosis. It is a valuable reagent for studies focused on cadmium-induced cellular damage and neuroprotection. -
mAChR Ligand
Azacyclonol hydrochloride is a selective ligand for the M3 muscarinic acetylcholine receptor, demonstrating significant inhibition of proliferation in androgen-refractory cancer cell lines, including DU145 and PC-3. This compound exhibits notable anticancer activity, particularly in A549 human lung cancer cells, by inhibiting NOX-derived reactive oxygen species. Additionally, Azacyclonol hydrochloride has shown antitumor effects in xenografted chorioallantoic membrane models. Beyond its anticancer applications, it is also explored for its potential in the treatment of chronic schizophrenia. -
Pancreatic Lipase/Acetylcholinesterase/Glutamic-oxaloacetic Transaminase 1/Alpha-glucosidase Inhibitor
Aspulvinone H is a potent inhibitor targeting pancreatic lipase, acetylcholinesterase, glutamic-oxaloacetic transaminase 1 (GOT1), and α-glucosidase, with IC50 values of 25.95 μM, 47.06 μM, 5.91/6.91 μM, and 4.6 μM, respectively. It demonstrates key biological activities including inhibition of cancer cell proliferation, disruption of glutamine metabolism, and induction of apoptosis in cancer cells. Additionally, Aspulvinone H lowers postprandial blood glucose levels in mice and exhibits antibacterial properties against Staphylococcus aureus. This compound is suitable for research into pancreatic ductal adenocarcinoma, diabetes management, and infectious diseases caused by Staphylococcus aureus. -
Cysteine Analog
D-Ribose-L-cysteine is an orally active cysteine analog that enhances intracellular glutathione (GSH) biosynthesis, thereby improving cellular antioxidant capacity. This compound exhibits memory-enhancing effects and can reverse Scopolamine-induced memory impairment through the inhibition of oxidative stress and acetylcholinesterase (AChE) activity. D-Ribose-L-cysteine is valuable for research on neurodegenerative and cardiovascular diseases, providing insights into therapeutic strategies for these conditions. -
CaMK II Inhibitor
KN-93 hydrochloride is a potent and selective inhibitor of calmodulin-dependent kinase type II (CaMKII), functioning through a reversible and competitive mechanism with an inhibition constant (Ki) of 370 nM. This compound is widely utilized in research involving calcium signaling pathways and neuronal activity modulation. Its ability to inhibit CaMKII makes it valuable for studies investigating cardiac function, neurodegenerative diseases, and synaptic plasticity. -
TFEB Activator
TFEB Activator 2 is a potent oral compound that effectively crosses the blood-brain barrier, targeting the dopamine transporter (DAT). It promotes TFEB nuclear translocation and enhances lysosome biogenesis through modulation of the DAT-CDK9-TFEB signaling pathway. With demonstrated neuroprotective properties, this reagent is valuable for research applications related to Alzheimer's disease and other neurodegenerative conditions. -
CaMKII Substrate
Autocamtide 2 is a selective peptide substrate for calcium/calmodulin-dependent protein kinase II (CaMKII). This reagent is primarily utilized in assays to measure CaMKII activity, providing valuable insights into cellular signaling pathways influenced by calcium. Its specificity ensures reliable results in research applications involving calcium-dependent processes. -
CaMKII Inhibitor
Autocamtide-2-related inhibitory peptide, myristoylated is a potent and selective inhibitor of CaMKII, exhibiting an IC50 of 40 nM. This peptide is used in research applications to investigate the regulatory mechanisms of calcium-dependent signaling pathways. Its myristoylation enhances its membrane permeability, facilitating in vivo studies of CaMKII activity and function in various cellular contexts. -
Cholinesterase (ChE) Inhibitor
Sophoflavescenol is a prenylated flavonol that acts as a cholinesterase (ChE) inhibitor, demonstrating potent inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 10.98 μM and 8.21 μM, respectively. Additionally, it shows significant inhibition of other enzymes, including RLAR, HRAR, and BACE1. This compound is primarily utilized in research related to neurodegenerative diseases and cognitive function enhancement, making it a valuable reagent for studying cholinergic pathways. -
COX Inhibitor
Aspirin DL-lysine is a lysine-conjugated derivative of aspirin that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively inhibits the synthesis of thromboxane A2 (TXA2) in platelets, leading to a reduction in platelet activation and aggregation. Aspirin DL-lysine is valuable for research applications focused on thrombin generation, particularly in clinical studies involving unstable angina pectoris. -
p38α MAPK/BChE Inhibitor
ARRY-371797 is a potent and orally bioavailable inhibitor of p38α MAPK and butyrylcholinesterase (BChE), demonstrating IC50 values of 12.0 µM for p38α MAPK and 0.13 µM for BChE, with minimal activity against human acetylcholinesterase (hAChE). This compound shows promise for research applications in Alzheimer’s disease, particularly in the context of neuroinflammation and cholinergic system modulation. -
P2Y14 Receptor Agonist
MRS2690 is a selective agonist of the P2Y14 receptor, primarily known for its role in the inhibition of adenylyl cyclase activity, which leads to a reduction in intracellular cAMP levels. This compound mediates concentration-dependent vasoconstriction in porcine coronary arteries and induces intracellular calcium mobilization. Additionally, MRS2690 activates p38 MAPK and stimulates [35S]GTPγS binding in RBL-2H3 cell membranes. It also enhances β-hexosaminidase release in response to antigen and complement activation, making it a valuable tool for research in ischemic heart disease. -
CaMKK2 Inhibitor
CC-3240 is a highly selective inhibitor of CaMKK2, exhibiting a potent inhibitory effect with an IC50 of 9 nM. This molecular glue degrader, developed from CC-8977, effectively disrupts the function of CaMKK2, making it a valuable tool for investigations into calcium and calcium/calmodulin-dependent signaling pathways. CC-3240 is particularly useful in research applications aimed at exploring the role of CaMKK2 in cellular processes and disease states. -
BChE Inhibitor
Pteryxin is a potent butyrylcholinesterase (BChE) inhibitor (IC50 = 12.96 μg/mL) with additional multi-target mechanisms including inhibition of NF-κB, MAPK, NLRP3 inflammasome activation, and modulation of the Nrf2/ARE pathways. This compound demonstrates significant anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin is suitable for research applications related to inflammatory diseases, osteoporosis, diabetes, and neurodegenerative disorders such as Alzheimer's disease. -
P2Y14R Antagonist
P2Y14R Antagonist 1 is a highly selective antagonist of the P2Y14 receptor, exhibiting an IC50 of 0.6 nM. It demonstrates significant antagonistic activity against P2Y14R, with both in vitro and in vivo efficacy, along with favorable pharmacokinetic properties. This compound effectively reduces the release of inflammatory mediators and mitigates cell pyroptosis through the NLRP3/Gasdermin D signaling pathway. P2Y14R Antagonist 1 is a valuable tool for research investigating acute gouty arthritis and related inflammatory conditions. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
P2X7 Modulator
GSK-1482160 is a negative allosteric modulator of the P2X7 receptor (P2X7R), with high oral bioavailability and the ability to penetrate the blood-brain barrier. It has demonstrated a human pIC50 of 8.5 and a rat pIC50 of 6.5, effectively reducing ATP's efficacy at the receptor without altering its affinity, which subsequently inhibits IL-1β release. This compound serves as a valuable radioligand for P2X7R imaging using isotopes such as 11C or 18F and is applicable in research related to chronic joint pain and chronic constriction injury (CCI). -
P2X7R Activitor
HEI3090 is a potent P2X7 receptor (P2X7R) activator. It effectively stimulates dendritic cells that express P2X7R to release IL-18, promoting the activation of Natural Killer cells and CD4 T cells. This cascade results in increased production of IFN-γ, thereby fostering a sustained antitumor immune response. HEI3090 is particularly beneficial in enhancing the efficacy of αPD-1 therapy for non-small cell lung cancer (NSCLC). -
Anti-Inflammatory Compound
Cynandione A is an acetophenone compound with anti-inflammatory properties. It has been shown to protect hepatocytes and cortical neurons from toxicity, as well as improve neurological deficits in a rat model of cerebral ischemia. Additionally, Cynandione A exerts significant anti-inflammatory effects through the activation of macrophage α7 nAChR and the expression of IL-10, making it a valuable tool for research in neuroprotection and inflammation. -
P2X7 Receptor Inhibitor
P2X7-IN-2 is a potent inhibitor of the P2X7 receptor, demonstrating an IC50 value of 0.01 nM for the inhibition of IL-1β release. This compound is valuable in research focusing on the mechanisms of autoimmunity, inflammation, and cardiovascular disease. Its selective action on the P2X7 receptor makes it a critical tool for studying inflammatory pathways and potential therapeutic interventions. -
COX Inhibitor
(±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications. -
AChE/BChE/BACE-1 Inhibitor
AChE/BChE/BACE-1-IN-1 is a potent inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-secretase 1 (BACE-1), exhibiting IC50 values of 0.058 μM, 0.082 μM, and 0.115 μM, respectively. This compound demonstrates significant binding affinity for the peripheral anionic site of AChE, facilitates brain penetration, and shows potential in disrupting amyloid-beta (Aβ) aggregates. Additionally, AChE/BChE/BACE-1-IN-1 exhibits neuroprotective properties against Aβ-induced stress and possesses promising antioxidant activity, making it a valuable tool for Alzheimer's disease research and related neurodegenerative studies. -
AChE/BChE Inhibitor
AChE/BChE-IN-9 is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 5.74 μM and 14.05 μM, respectively. In addition to its enzymatic inhibition, AChE/BChE-IN-9 demonstrates antioxidant properties with an IC50 of 57.35 μM and has the ability to chelate iron, potentially mitigating oxidative stress. This compound also influences the aggregation of amyloid β1-42, making it relevant for research in neurodegenerative diseases and gerontology. Its capacity to cross the blood-brain barrier further enhances its suitability for studies focused on central nervous system disorders.
